Literature DB >> 26202412

Hepatitis C viral load predicts tumor recurrence after curative resection of hepatocellular carcinoma regardless of the genotype of hepatitis C virus.

Junichi Shindoh1, Kiyoshi Hasegawa2, Nobuyuki Takemura2, Kiyohiko Omichi2, Takeaki Ishizawa2, Taku Aoki2, Yoshihiro Sakamoto2, Yasuhiko Sugawara2, Norihiro Kokudo3.   

Abstract

PURPOSE: To clarify the prognostic impact of the hepatitis C virus (HCV) genotype after curative resection for hepatocellular carcinoma (HCC).
METHODS: A total of 199 patients who underwent a curative hepatic resection for HCV-related HCC were reviewed. The clinical outcomes were compared between patients infected with HCV genotype 1b (n = 160) and those infected with other genotypes (n = 39).
RESULTS: With a comparable median HCV viral load (6.0 vs. 5.8 log10 IU/mL, p = 0.17), the 3-year recurrence-free survival (RFS) rates (25 vs. 20 %, p = 0.65) and the 5-year overall survival (OS) rates (72 vs. 65 %, p = 0.73) were similar between the two groups. A multivariate analysis confirmed that HCV viral load of +1.0 log10 IU/mL [hazard ratio (HR), 1.48], major vascular invasion (HR, 3.20), recurrent tumor (HR, 1.77), and preoperative des-gamma carboxyprothrombin level >40 mAu/mL (HR, 1.64) were independent predictors of tumor recurrence, while the HCV genotype was not a significant risk factor. When the population was stratified according to the HCV viral load, a significant difference was observed in the RFS rate for both genotype 1b (p = 0.003) and the other genotypes (p = 0.037) at HCV viral load of 5.3 log10 IU/mL.
CONCLUSIONS: The HCV genotype does not affect the surgical outcomes of patients with HCC. A lower HCV viral load is advantageous regardless of the HCV genotype.

Entities:  

Keywords:  Genotype; Hepatitis C; Hepatocellular carcinoma; Surgery; Viral load

Year:  2013        PMID: 26202412     DOI: 10.1007/s12072-013-9507-3

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  38 in total

Review 1.  Pathologic characteristics of hepatocellular carcinoma.

Authors:  T Nakashima; M Kojiro
Journal:  Semin Liver Dis       Date:  1986-08       Impact factor: 6.115

Review 2.  Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.

Authors:  Vincenza Conteduca; Domenico Sansonno; Sabino Russi; Fabio Pavone; Franco Dammacco
Journal:  J Infect       Date:  2013-09-04       Impact factor: 6.072

3.  Relationship between response to previous interferon therapy and postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma.

Authors:  Takahiro Uenishi; Shoji Kubo; Kazuhiro Hirohashi; Hiromu Tanaka; Taichi Shuto; Takatsugu Yamamoto; Akihiro Tamori; Seikan Hai; Hiroaki Kinoshita; Shuhei Nishiguchi
Journal:  Hepatol Res       Date:  2002-12       Impact factor: 4.288

4.  Influence of interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma.

Authors:  Takahiro Uenishi; Shuhei Nishiguchi; Akihiro Tamori; Takatsugu Yamamoto; Taichi Shuto; Kazuhiro Hirohashi; Shigekazu Takemura; Hiromu Tanaka; Shoji Kubo
Journal:  Hepatol Res       Date:  2006-08-24       Impact factor: 4.288

5.  Risk factors for recurrence after resection of hepatitis C virus-related hepatocellular carcinoma.

Authors:  S Kubo; K Hirohashi; H Tanaka; T Tsukamoto; T Shuto; T Ikebe; T Yamamoto; K Wakasa; S Nishiguchi; T Kuroki; H Kinoshita
Journal:  World J Surg       Date:  2000-12       Impact factor: 3.352

6.  Long-term outcome after surgery for asymptomatic small hepatocellular carcinoma.

Authors:  C S Lee; J C Sheu; M Wang; H C Hsu
Journal:  Br J Surg       Date:  1996-03       Impact factor: 6.939

7.  Risk factors for hepatocellular carcinoma among patients with chronic liver disease.

Authors:  H Tsukuma; T Hiyama; S Tanaka; M Nakao; T Yabuuchi; T Kitamura; K Nakanishi; I Fujimoto; A Inoue; H Yamazaki
Journal:  N Engl J Med       Date:  1993-06-24       Impact factor: 91.245

8.  Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study.

Authors:  Kazuki Ikeda; Hiroyuki Marusawa; Yukio Osaki; Takefumi Nakamura; Naoto Kitajima; Yukitaka Yamashita; Masatoshi Kudo; Tosiya Sato; Tsutomu Chiba
Journal:  Ann Intern Med       Date:  2007-05-01       Impact factor: 25.391

9.  Early hepatocellular carcinoma as an entity with a high rate of surgical cure.

Authors:  T Takayama; M Makuuchi; S Hirohashi; M Sakamoto; J Yamamoto; K Shimada; T Kosuge; S Okada; K Takayasu; S Yamasaki
Journal:  Hepatology       Date:  1998-11       Impact factor: 17.425

10.  Low hepatitis C viral load predicts better long-term outcomes in patients undergoing resection of hepatocellular carcinoma irrespective of serologic eradication of hepatitis C virus.

Authors:  Junichi Shindoh; Kiyoshi Hasegawa; Yutaka Matsuyama; Yosuke Inoue; Takeaki Ishizawa; Taku Aoki; Yoshihiro Sakamoto; Yasuhiko Sugawara; Masatoshi Makuuchi; Norihiro Kokudo
Journal:  J Clin Oncol       Date:  2012-11-05       Impact factor: 44.544

View more
  2 in total

Review 1.  Surgical approach for hepatitis C virus-related hepatocellular carcinoma.

Authors:  Junichi Shindoh; Masaji Hashimoto; Goro Watanabe
Journal:  World J Hepatol       Date:  2015-01-27

2.  A Novel Nomogram Model to Predict the Recurrence-Free Survival and Overall Survival of Hepatocellular Carcinoma.

Authors:  Shu-Wen Zhang; Ning-Ning Zhang; Wen-Wen Zhu; Tian Liu; Jia-Yu Lv; Wen-Tao Jiang; Ya-Min Zhang; Tian-Qiang Song; Li Zhang; Yan Xie; Yong-He Zhou; Wei Lu
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.